Immune thrombocytopenia · 13 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Eltrombopag monotherapy Variant #01 | — | R 39 588 | 28d | — | — | — | — | — |
Dexamethasone and Rituximab Variant #01 | — | R 24 005 | 14d | — | — | — | — | — |
ATRA and Danazol Variant #01 | — | R 16 221 | 112d | — | — | — | — | — |
Cyclosporine monotherapy Variant #03 | — | R 2 156 | — | — | — | — | — | — |
Danazol monotherapy Variant #01 | — | R 1 870 | 112d | — | — | — | — | — |
Dexamethasone monotherapy Variant #11 | — | R 1 389 | 35d | — | — | — | — | — |
Mycophenolate mofetil monotherapy Variant #01 | — | R 1 356 | 28d | — | — | — | — | — |
Rituximab monotherapy N/A - secondary systemic drug | — | R 52 | 180d | ~20.3 mo | — | ~4 | ~R 208 PFS proxy · indirect | 20 |
Romiplostim monotherapy Variant #01 Partial | — | — | 7d | — | — | — | — | — |
Vinblastine-loaded platelets Partial | — | — | — | — | — | — | — | — |
Placebo Partial | — | — | — | ~4.2 mo | ~8.0 mo | — | — | 145 |
Fostamatinib monotherapy Variant #01 Partial | — | — | 168d | — | — | — | — | — |
Avatrombopag monotherapy Variant #01 Partial | — | — | 5d | — | — | — | — | — |
13 of 13 regimens shown